The majority of compounds in today’s development pipelines have properties requiring bioavailability enhancement to ensure that adequate exposure can be consistently obtained during preclinical and clinical assessment. These compounds must be paired with the right enabling technology for rapid progression. This webinar will focus on the scientific rationale for selecting key technologies based on a compound’s properties and product specifications. A fundamental model-based approach, leveraging the extensive study and mapping of hundreds of compounds, will be presented along with case studies.
Senior Vice President